Subacute Cutaneous Lupus Erythematosus.
|
Accession number;02A0208862
|
| Title;Subacute Cutaneous Lupus Erythematosus. |
| Author;
HIRAKATA MICHITO
(Sch. of Med., Keio Univ.)
|
Journal Title;Prog Med
|
Journal Code:F0664B
|
ISSN:0287-3648
|
|
VOL.22;NO.1;PAGE.66-69(2002)
|
| Figure&Table&Reference;FIG.3, TBL.1, REF.11 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Subacute cutaneous lupus erythematosus (SCLE) was first presented by Gilliam and Sontheimer as a distinct form of cutaneous LE, since the histologic changes in this superficial form seem intermediate between chronic cutaneous LE (Discoid LE) and the transient acute malar erythema. The hallmarks of SCLE lesions are nonfixed, nonscarring, papulosquamous or annular erythema (or both) which have an LE-specific histopathology demonstrating liquefaction degeneration of basal cell and a mononuclear cell infiltration around the dermal-epidermal junction, and which occur in a characteristic sun-exposed areas (i.e. upper back, shoulders, extensor aspects of the arms, V-area of the neck, and on the face). The cutaneous lesions of papulosquamous SCLE are most closely mimicked by those of psoriasis. Annular SCLE lesions are similar to annular erythema associated with Sjoegren's syndrome. SCLE is a distinct clinical subset of LE skin disease that occur in a relatively homogenous group of patients who have anti-SS-A/Ro and/or anti-SS-B/La autoantibodies and are frequently of the DR-3 phenotype in U.S. Caucasian. Patients with SCLE often have a mild form of systemic lupus erythematosus, characterized by musculoskeletal symptoms including arthralgia/arthritis, myalgia, and a low incidence of severe central nervous system or renal involvement. Potent topical corticosteroids are applied to the cutaneous lesions twice daily for a 2-week period of time and effective forms of therapy. Oral corticosteroids (prednisolone in 20 to 40 mg/day) are frequently successful. (author abst.) |
|
|
|
Related Articles;
|
|
